We are live on
!
Find out more
BCA
Benchmark Capital Advisors Portfolio holdings
AUM
$101M
1-Year Est. Return
0.8%
This Fund
S&P 500
This Quarter
Est. Return
+6.65%
1 Year Est. Return
-0.8%
3 Year Est. Return
+29.53%
5 Year Est. Return
+43.22%
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$5.73M
(+4.5%)
Cap. Flow
-$179K
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
31.6%
Holding
141
New
11
Increased
30
Reduced
56
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$1.64M |
| 2 |
Newell Brands
NWL
|
+$1.16M |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.05M |
| 4 |
Apple
AAPL
|
+$1.02M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$1,000K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$2.2M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$1.44M |
| 3 |
Viasat
VSAT
|
+$1.26M |
| 4 |
iShares Europe ETF
IEV
|
+$1.17M |
| 5 |
Novartis
NVS
|
+$1.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 17.42% |
| 2 | Technology | 15.72% |
| 3 | Real Estate | 14.11% |
| 4 | Healthcare | 13.29% |
| 5 | Financials | 11.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
McDonald's
MCD
$184B
| – | – |
-1,384
| Closed | -$216K |
|
127
Micron Technology
MU
$1.06T
| – | – |
-6,500
| Closed | -$339K |
|
|
128
Novartis
NVS
$294B
| – | – |
-14,843
| Closed | -$1.07M |
|
129
Vanguard FTSE Europe ETF
VGK
$31B
| – | – |
-7,325
| Closed | -$426K |
|
|
130
Viasat
VSAT
$10B
| – | – |
-19,250
| Closed | -$1.26M |
|
|
GNH
131
DELISTED
GLOBAL ENERGY HOLDINGS GROUP INC COM STK
GNH
| $0 | ﹤0.01% |
69,447
| – | – |
|
Similar funds
OIMU
7A
JCP
DCM
BCEM
QAM
CFA
BPV
Benchmark Capital Advisors's Q2 2018 Portfolio in Review
As of Q2 2018, Benchmark Capital Advisors held 141 positions worth $132M, up 4.5% from $127M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Benchmark Capital Advisors's Q2 2018 filing shows 11 new, 30 increased, 56 reduced and 10 closed positions. Its largest new stake was Merck: 29,082 shares worth $1.68M. The largest sale was Bristol-Myers Squibb, an estimated $2.2M.
By sector, the portfolio is most concentrated in Miscellaneous at 17% of assets, down from 20% a quarter earlier, followed by Technology and Real Estate.
- Benchmark Capital Advisors's largest Q2 2018 buy was Merck: 29,082 shares worth $1.68M.
- Benchmark Capital Advisors added most to Meta Platforms (Facebook) in Q2 2018, an estimated $1.05M increase.
- Benchmark Capital Advisors's biggest Q2 2018 reduction was Bristol-Myers Squibb, cutting an estimated $2.2M.
- Benchmark Capital Advisors fully exited Viasat in Q2 2018, selling an estimated $1.26M.
- Benchmark Capital Advisors's ten largest holdings make up 32% of its $132M portfolio in Q2 2018.
- Benchmark Capital Advisors opened 11 new positions and closed 10 in Q2 2018.
- Benchmark Capital Advisors's portfolio value rose 4.5% quarter-over-quarter to $132M.
Based on Benchmark Capital Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.